1842427-90-0
Chemical Structure
FX 2149
- CAS No.: 1842427-90-0
- Formula:C15H17N3O3S
- Molecular Weight:319.38
IUPAC Name: N-propyl-3-(pyridine-3-sulfonamido)benzamide
InChIKey: LMLYPZLOEZIJGY-UHFFFAOYSA-N
SMILES: O=C(NCCC)C=1C=CC=C(C1)NS(=O)(=O)C=2C=NC=CC2
Biological Activity: FX 2149 is a blood-brain barrier-permeable LRRK2 inhibitor. FX 2149 inhibits the GTP-binding activity of LRRK2, reduces the kinase activity of LRRK2, and attenuates LPS (HY-D1056)-induced upregulation of LRRK2. FX 2149 alleviates mutant LRRK2-induced neurodegeneration, microglial activation, static aggregation of mitochondria and lysosomes, reduces apoptosis, and improves mitochondrial and lysosomal motility deficits in neurites. FX 2149 can be used in research related to Parkinson's disease[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
FX 2149 | FX 2149 is a blood-brain barrier-permeable LRRK2 inhibitor. FX 2149 inhibits the GTP-binding activity of LRRK2, reduces the kinase activity of LRRK2, and attenuates LPS (HY-D1056)-induced upregulation of LRRK2. FX 2149 alleviates mutant LRRK2-induced neurodegeneration, microglial activation, static aggregation of mitochondria and lysosomes, reduces apoptosis, and improves mitochondrial and lysosomal motility deficits in neurites. FX 2149 can be used in research related to Parkinson's disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Li T, et al. A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models. PloS one. 2015;10(3):e0122461. [Content Brief]
- [2]. Thomas JM, et al. 68 and FX2149 Attenuate Mutant LRRK2-R1441C-Induced Neural Transport Impairment. Frontiers in aging neuroscience. 2016;8:337. [Content Brief]
